Pharmaceutical Executive Daily: US Senate Passes Biosecure Act
Dec 19, 2025, 06:46 PM
Share
Subscribe
In today’s Pharmaceutical Executive Daily, Eli Lilly announces positive topline Phase III data for its oral GLP-1 candidate orforglipron, the U.S. Senate passes the Biosecure Act with implications for biopharma supply chains, and industry experts examine how rebate consultants are shaping biosimilar adoption.